TH59183B - Peptides for the treatment of cancer involving human papilloma virus (HPV) and other epithelial tissue tumors. - Google Patents

Abstract

DC60 (29/01/56) This invention relates to the field of molecular pharmaceuticals and in particular to the creation of Peptides are useful for treating epithelial tumors and are primarily associated with orthogenetic HPVs. The main objective of this invention is to indicate the peptide whose structure It blocks the phosphorylation domain of casein kinase II (CKII) by direct interaction with these locations. Eleven peptide chains with different amino acid sequences have been shown. The phosphorylation inhibitors of CKII in vitro showed cytotoxicity on treated cells. Transformed with HPV-16 (CaSki) and also increased the sensitivity of these cells to the stagnant effect. Moreover, this invention involves the use of these peptides that are conjugated or fused with other peptides and chemical compounds which penetrate the cell as well. with Using both peptides and chemical molecules This invention relates to the field of molecular pharmaceuticals and in particular to the creation of Useful peptides for the treatment of epithelial tumors and in association with oncogenic HPVs. The main objective of this invention is to indicate the peptide whose structure It blocks the phosphorylation domain of casein kinase II (CKII) by direct interaction with these locations. Eleven peptide chains with different amino acid sequences have been shown. The phosphorylation inhibitors of CKII in vitro showed cytotoxicity on treated cells. Transformed with HPV-16 (CaSki) and also increased the sensitivity of these cells to the stagnant effect. Moreover, this invention involves the use of these peptides that are conjugated or fused with other peptides and chemical compounds which penetrate into cells such as same as The use of both polypeptides and chemical molecules

Claims (3)

Claims (all) which will not appear on the advertisement page: Amendment 08/03/2017 1 1. Any of the 8-10 claim peptides. Which includes additionally Cytokine for use in the manufacture of medicinal products 1 2. Peptide according to claim 11, where cytokine is IFN 1. 3. Which peptide according to claim 8-10? One For use in the manufacture of medicinal products HPV-resistant patients to IFN 1 therapy. 4. Vector for characterization of mammals with nucleic acid coded nucleic acid. For the peptides listed in any of the preceding claims 1 5. Peptides according to claim 4, where the fusion peptide is composed of the peptide that has penetrated Through cell 1 6. Peptide according to claim 15, where the peptide penetrating the cell is the HIV-1 Tat-1 protein ----------------- ------ 1. Peptides for inhibition of the phosphorylation location of casein kinase II (CKII) in which the peptides are sequenced in the following order: a CSVRQGPVQKC. ; b CSSCQNSPALC; c CQIPQRTATRC; d CAKQRTDPGYC; e CWMSPRHLGTC; f CRNCTVIQFSC; g CHYLAGTVQGC; h CPLVSLRDHSC; i CKQSYLHHLLC; j CFQPLTPLCRC; or k CQSYHELLLQS 2. . Peptides according to claim 1 or 2, which are contained in fused polypeptides. 4. Pharmaceutical mixtures consisting of one peptide. Or a different peptide of Clause 1-3, any one The same applies to the appropriate carrier 5. The pharmaceutical mixture according to claim 4, which is supplemented with cytokine 6. The pharmaceutical mixture according to claim 5, whose cytokine is interphase. Ron (IFN) 7. Use of peptides in accordance with Clause 1-3. 8. Use according to claim 7 for the treatment of both HPV-associated tumors and non-HPV-associated tumors. 9. Use of peptides for the treatment of non-HPV lesions. HPV at the Pre-Serious Phase 1 0. Use of any of Claim 7-9 which uses PE Tide in combination with cytokine 1 1. Use according to claim 10, where the cytokine is IFN 1. 2. Use according to the claim 7-9, any one of which uses PEP Tide for the treatment of HPV-resistant patients to IFN 1 therapy. 3. A vector to characterize a mammal. With a coded DNA sequence For any of the peptides present in any of the 1-3 Claims